{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000494","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.951566+00:00","generated_at":"2026-06-26T03:11:17.426552+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alnylam Q1 product revenue $187M, GAAP loss $240M; lowers 2022 guidance to $870-930M","bullets":["Q1 total net product revenue $187M (+38% YoY); GAAP net loss $240M ($2.00 EPS), non-GAAP loss $180M ($1.49 EPS).","Lowered 2022 combined revenue guidance to $870-930M from $900M-$1B due to Q1 pandemic impact and non-recurring Q4 2021 benefits.","FDA extended vutrisiran NDA review to July 14, 2022; company expects launch upon approval if cleared.","Patient growth: ONPATTRO >2,200 (+7%), GIVLAARI >400 (+14%), OXLUMO >160 (+14%) QoQ.","Initiated Phase 1 for ALN-APP (Alzheimer's) and ALN-XDH (gout); filed patent suits against Pfizer/Moderna for COVID-19 vaccine lipids."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000494","json":"https://secwatch.observer/filing/0001157523-22-000494.json","markdown":"https://secwatch.observer/filing/0001157523-22-000494.md","text":"https://secwatch.observer/filing/0001157523-22-000494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000115752322000494/0001157523-22-000494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000115752322000494/a52699629.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:11:17.426552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}